Breadcrumb

  1. Our scientific focus
  2. Research and development
  3. The development pipeline

The development pipeline

Merging global experience and technology to offer patients a brighter future

To promote our network-based drug discovery and global R&D efforts, Santen is placing significant emphasis on strengthening our relationships with universities, research organisations and other pharmaceutical firms to conceive new treatments for patients around the world. We hope such relationships will lead to the discovery and launch of novel therapies for severe dry eye disease, glaucoma, diabetic macular oedema and uveitis, a condition with limited treatment options.

Pipeline of prescription pharmaceuticals (clinical stage) As of October 2020

Filter indication

Sirolimus DE-109 (STN10109)

An intravitreal injection with immunosuppressive effect, anti-angiogenic effect, etc. Started an additional Phase 3 in December 2018 in the U.S. Filed for marketing approval in April 2015 in Asia.

Indication
Original/Licensor
Uveitis
Original
 
P1
P2
P3
NDA filed
Approved
Launched
U.S.
Japan
Europe
Asia
Apr 2015
Tafluprost/timolol maleate DE-111 (STN10111)

A fixed dose combination drug of a prostaglandin F derivative and a beta-adrenergic receptor blocker. Launched in Japan in November 2014. Launched successively in European countries since January 2015. Launched successively in Asian countries since April 2016. Started Phase 3 in January 2019 in China.

Indication
Original/Licensor
Glaucoma
• Ocular hypertension
Co-development with AGC
 
P1
P2
P3
NDA filed
Approved
Launched
China
Omidenepag isopropyl DE-117 (STN10117)

An EP2 receptor agonist with a new mechanism of action. Started Phase 3 in September 2018 in the U.S. Launched in November 2018 in Japan. Received successively marketing approval in Korea in December 2019 with successive filings planned for Asian countries.

Indication
Original/Licensor
Glaucoma
• Ocular hypertension
Co-development with Ube Industries
 
P1
P2
P3
NDA filed
Approved
Launched
U.S.
Japan
Nov 2018
Asia
Dec 2019
Sepetaprost DE-126 (STN10126)

A prostaglandin analogue eye drop drug product with a novel mode of action that is a dual agonist for both FP and EP3 receptors for the treatment of glaucoma and ocular hypertension. Completed Phase 2b in the U.S. and Japan.

Indication
Original/Licensor
Glaucoma
• Ocular hypertension
ONO PHARMACEUTICAL
 
P1
P2
P3
NDA filed
Approved
Launched
U.S.
(Phase 2b)
Japan
(Phase 2b)
Atropine sulfate DE-127 (STN10127)

Muscarinic antagonist which reduces juvenile myopia progression. Started Phase 2/3 in August 2019 in Japan. Completed Phase 2 in April 2020 in Asia. 

Indication
Original/Licensor
Myopia
Singapore Health Services, Nanyang Technological University
 
P1
P2
P3
NDA filed
Approved
Launched
Japan
(Phase 2/3)
Asia
PRESERFLO™ MicroShunt* (DE-128)

In August 2016, Santen acquired InnFocus, developer of PRESERFLO™ MicroShunt*, a drainage implant device designed to lower and sustain intraocular pressure (IOP) for the treatment of primary open-angle glaucoma through the drainage of aqueous humour. Completed pre-market approval rolling submission to the FDA in June 2020 in the U.S. Launched in Europe in January 2019. Filed successively for marketing approval in Asian countries following Korean filing in March 2020.

Indication
Original/Licensor
Glaucoma
Original
 
P1
P2
P3
NDA filed
Approved
Launched
U.S.
Jun 2020
Europe
Jan 2019
Asia
Mar 2020

*PRESERFLO™ is the new trademark of Innfocus MicroShunt®. PRESERFLO™ MicroShunt will replace Innfocus MicroShunt® in the future.

Latanoprost DE-130A (STN10130, Catioprost)

An ophthalmic emulsion of a prostaglandin F derivative, for the treatment of glaucoma and ocular hypertension. Started Phase 3 in April 2019 in Europe and Asia.

Indication
Original/Licensor
Glaucoma
• Ocular hypertension
Original
 
P1
P2
P3
NDA filed
Approved
Launched
Europe
Asia
Intraocular lens (MD-16)

A toric intraocular lens to treat aphakia after cataract surgery. Received manufacturing and marketing approval in Japan in November 2019.

Indication
Original/Licensor
Cataract
Oculentis
 
P1
P2
P3
NDA filed
Approved
Launched
Japan
Nov 2019

No changes from Q1 FY20 (February 2020)

Santen discloses the information on the ongoing clinical studies to confirm safety and efficacy of our drugs on the websites as below.